Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + bevacizumab + HAIC FOLFOX as first-line therapy for unresectable hepatocellular carcinoma
ChiCTR2600128357Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jul 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib, bevacizumab, oxaliplatin, folinic acid and fluorouracil in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Objective Response Rate (RECIST v1.1). Started Jul 2026; status: recruiting.
02
Drugs
anlotinibbevacizumaboxaliplatinfolinic acidfluorouracil
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2600128357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128357.